Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373503 · ClinicalTrials.gov registry record · Phase 2
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00373503 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants.
The verdict
NCT00373503, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the interaction between marijuana and two potential treatment medications: lofexidine and oral THC, with the direct goal of using this information to improve marijuana treatment outcome.
Interventions
- DRUG Lofexidine
- DRUG Marijuana
- DRUG dronabinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373503
The ClinicalTrials.gov registry entry for NCT00373503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lofexidine is the first listed.
NCT00373503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373503 about?
NCT00373503 is a clinical study titled "Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse". The purpose of this study is to investigate the interaction between marijuana and two potential treatment medications: lofexidine and oral THC, with the direct goal of using this information to improve marijuana treatment outcome.
What is the current status of trial NCT00373503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2005-08. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00373503?
The interventions under investigation include: Lofexidine (DRUG), Marijuana (DRUG), dronabinol (DRUG).
Who is sponsoring clinical trial NCT00373503?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.